DEGOEY, David A.,KATI, Warren M.,HUTCHINS, Charles W.,DONNER, Pamela L.,KRUEGER, Allan C.,RANDOLPH, John T.,PATEL, Sachin V.,MATULENKO, Mark A.,KEDDY, Ryan G.,JINKERSON, Tammie K.,LIU, Dachun,PRATT, J
申请号：
ES12716757
公开号：
ES2624246T3
申请日:
2012.02.24
申请国别(地区):
ES
年份:
2017
代理人:
摘要：
The compound {(2S, 3R) -1 - [(2S) -2- {5 - [(2R, 5R) -1- {3,5-difluoro-4- [4- (4-fluorophenyl) piperidin-1 -yl] phenyl} -5- (6-fluoro-2- {(2S) -1- [N- (methoxycarbonyl) -O-methyl-L-threonyl] pyrrolidin-2-yl} -1H-benzimidazole-5- yl) pyrrolidin-2-yl] -6-fluoro-1H-benzimidazol-2-yl} pyrrolidin-1-yl] -3-methoxy-1-oxobutan-2-yl} carbamate, or a pharmaceutically acceptable salt thereof, for use in a method of treating a patient infected with HCV genotype 1 patient, said method comprising administering an effective amount of said compound to said patient.El compuesto {(2S,3R)-1-[(2S)-2-{5-[(2R,5R)-1-{3,5-difluoro-4-[4-(4-fluorofenil)piperidin-1-il]fenil}-5-(6-fluoro-2- {(2S)-1-[N-(metoxicarbonil)-O-metil-L-treonil]pirrolidin-2-il}-1H-benzimidazol-5-il)pirrolidin-2-il]-6-fluoro-1H-benzimidazol-2il}pirrolidin-1-il]-3-metoxi-1-oxobutan-2-il}carbamato de metilo, o una de sus sales farmacéuticamente aceptables, para su uso en un método de tratamiento de un paciente infectado con el genotipo 1 del VHC, comprendiendo dicho método la administración de una cantidad eficaz de dicho compuesto a dicho paciente.化合物{(2S,3R)-1-[(2S,3R)-1-[(2S)-1--[(2S,3S)-1---[(2S---------[(2S,3R)-1---[(2S,3R)-1------[(2S))-2---------[(2S)-2----------------[(2S)-2----------------------[(2S)-2---------------------------[(2S)-2----6-氟-1H-苯并咪唑-2-基}吡咯烷-1-基]- 3-甲氧基-1-氧代丁烷-2-基氨基甲酸酯,或其药学上可接受的盐,用于治疗感染HCV基因型1型患者的方法,所述方法包括向患者施用有效量的所述化合物。
